C4 Therapeutics stock price target raised to $10 by Wells Fargo on positive data

C4 Therapeutics (CCCC) saw Wells Fargo double its price target to $10.00 from $5.00, maintaining an Overweight rating, following updated clinical data for its cemsi treatment. The data, presented at the IMS meeting, highlighted a 53% overall response rate (ORR) at the 100ug dose and a 9.3-month duration of response, which Wells Fargo believes demonstrates superior efficacy and safety profiles compared to rival programs, even in heavily pre-treated patients. This positive clinical development has also led other firms like Barclays, Stephens, and Guggenheim to issue favorable ratings, suggesting potential upside for the currently undervalued stock despite recent volatility.

Analysis

C4 Therapeutics (NASDAQ:CCCC) has garnered significant positive analyst attention following the release of updated clinical data for its cemsi treatment in relapsed/refractory multiple myeloma. Wells Fargo doubled its price target to $10.00, citing a superior efficacy and safety profile compared to Bristol Myers Squibb's programs. The key data point is a 53% overall response rate (ORR) at the 100ug dose, an improvement from a prior 50% ORR, with a median duration of response (DoR) of 9.3 months across effective doses. Critically, cemsi's 40% ORR at the 75ug dose is comparable to a competitor's 41% rate, but was achieved in a more heavily pre-treated patient population (75% with prior BCMA exposure vs. 30% for the competitor), suggesting a potentially stronger clinical profile. This momentum is echoed by Barclays, Stephens, and Guggenheim, who have all issued Overweight or Buy ratings with price targets of $6.00 to $8.00. Despite these positive catalysts and a strong liquidity position indicated by a current ratio of 5.06, the stock exhibits significant risk, evidenced by a high beta of 3.0 and a recent 23% price decline, trading at $2.61 far below even the most conservative analyst targets.

Key Decisions for Investors

• Given the strong clinical data and multiple analyst upgrades, investors could view the substantial disconnect between the current stock price ($2.61) and analyst targets ($6-$50) as a potential long opportunity, catalyzed by cemsi's competitive clinical profile.
• The stock's high volatility, reflected by a 3.0 beta and a recent 23% weekly drop, necessitates careful position sizing and an acceptance of significant short-term price risk, even with the positive long-term outlook.
• Investors should monitor upcoming data from competitors and C4's planned webcast, as the durability of cemsi's response and its performance relative to rivals are central to the investment thesis.
• The negative sentiment towards competitor Bristol Myers Squibb (-0.4) suggests a potential pair trade or a re-evaluation of relative positioning within the multiple myeloma treatment space.